Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiviral drug
Azaribine
Другие языки:

    Azaribine

    Подписчиков: 0, рейтинг: 0
    Azaribine
    Azaribine.svg
    Clinical data
    Trade names Azaribine
    Legal status
    Legal status
    • US: Withdrawn drug
    Identifiers
    • [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(3,5-dioxo-1,2,4-triazin-2-yl)oxolan-2-yl]methyl acetate
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.016.832
    Chemical and physical data
    Formula C14H17N3O9
    Molar mass 371.3 g·mol−1
    3D model (JSmol)
    • CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C
    • InChI=1S/C14H17N3O9/c1-6(18)23-5-9-11(24-7(2)19)12(25-8(3)20)13(26-9)17-14(22)16-10(21)4-15-17/h4,9,11-13H,5H2,1-3H3,(H,16,21,22)/t9-,11-,12-,13-/m1/s1
    • Key:QQOBRRFOVWGIMD-OJAKKHQRSA-N

    Azaribine (triacetyl-6-azauridine) is a drug which was developed for the treatment of psoriasis, and also has anti-cancer and antiviral actions. It is a prodrug which is metabolised to the nucleoside analogue 6-azauridine in the body. Azaribine was approved for clinical use in treatment of psoriasis, but subsequently withdrawn because of toxicity issues, however it continues to be researched as a potential agent for the treatment of emerging viral diseases.


    Новое сообщение